FeelGood vs TMates: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

49 providers verified independently·Independent researchHow we rank →

TMates beats FeelGood overall, scoring 7.8/10 vs 7/10. FeelGood is more affordable at $149/mo vs $158/mo. Choose FeelGood for budget-conscious cash-pay patients who want low-cost compoun. Choose TMates for users who want flexible pricing across compounded glp-1s (me.

A side-by-side comparison of FeelGood and TMates covering pricing, scores, medication types, insurance, and more to help you decide.

FeelGood

#48 of 49
7/10

Telehealth platform offering compounded semaglutide as both a weekly injection ($149/mo starting) and a daily oral tablet ($249/mo starting), plus a premium brand-name 'original' semaglutide injection option ($1,999/mo). Cash-pay only, no insurance billing, HSA/FSA eligible. LegitScript-approved. FeelGood does not publicly disclose which states it serves, its compounding pharmacy, or its medical leadership.

Visit FeelGood
Higher Rated

TMates

#16 of 49
7.8/10

Telemedicine platform offering two distinct archetypes: compounded semaglutide and tirzepatide with medication included (commitment pricing $158-$249/mo), and a clinical-service-only path to brand-name Wegovy/Zepbound at $99/mo where the prescription is sent to the patient's pharmacy. Phentermine also available. 2026 expansion added brand-name FDA-approved options.

Visit TMates
FeatureFeelGoodTMates
Our Score7/107.8/10
Starting Price$149/mo$158/mo
Medication TypeBothBoth
Insurance AcceptedNoYes
Best ForBudget-conscious cash-pay patients who want low-cost compounded semaglutide — injection or oral tablet — with free shipping, no membership fees, and a money-back weight-loss guaranteeUsers who want flexible pricing across compounded GLP-1s (medication included, $158-$249/mo with commitment discounts) and a cheap clinical-service-only path to brand Wegovy or Zepbound ($99/mo, patient fills at own pharmacy)
Ranking#48#16

Pros & Cons Compared

FeelGood

Pros

  • +Compounded semaglutide injection from $149/mo with free shipping and no separate membership or consultation fee
  • +Offers an oral compounded semaglutide tablet ($249/mo) for needle-averse patients — a non-injectable route only a handful of platforms provide
  • +LegitScript-approved — independent certification that the telehealth/pharmacy operation meets legal and safety standards, which many budget compounded shops lack
  • +Money-back weight-loss guarantee plus unlimited 24/7 messaging and appointments included

Cons

  • Does NOT publicly disclose which US states it serves — you can't confirm availability in your state before starting an intake
  • $149 is a 'starting' price (dose-escalating), not flat across all doses — your cost can rise as your dose titrates up, and FeelGood doesn't publish the full dose-by-dose schedule
  • Brand-name 'original' semaglutide injection at $1,999/mo is far above market — NovoCare direct Wegovy is $349/mo and Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership. Never buy brand-name through FeelGood
  • No named medical director, prescribing physicians, compounding pharmacy, founding year, or headquarters disclosed on the site — thin corporate and clinical transparency
  • Self-reported '4.8/5' rating is not tied to a named third-party platform (no linked Trustpilot/BBB), so it can't be independently verified; the advertised '15–20% weight loss' figures are FeelGood's marketing, not FDA-reviewed efficacy data
  • Compounded GLP-1s are not FDA-approved (none are) — and FeelGood offers compounded semaglutide only, no tirzepatide

TMates

Pros

  • +Steep multi-month commitment discounts on compounded sema — $158/mo on 12-month plan ($1,900 upfront) vs $249/mo month-to-month
  • +Clinical-service-only path to brand Wegovy and Zepbound at $99/mo — prescription goes to patient's pharmacy (you fill separately using insurance or cash)
  • +Same price at all dose levels for compounded — no cost escalation as you titrate up
  • +Phentermine available at $149/mo for patients who benefit from a different appetite-suppressant approach

Cons

  • Brand Wegovy/Zepbound $99/mo is CLINICAL SERVICE ONLY — medication cost is separate (paid at your pharmacy, which can be $1,000+/mo cash without insurance)
  • Best compounded pricing requires 6-12 month prepayment (upfront $1,050-$1,900)
  • 90-second assessment quiz suggests convenience over clinical thoroughness compared to competitors with full medical intakes
  • Not affiliated with Novo Nordisk (Wegovy) or Eli Lilly (Zepbound) — TMates prescribes but does not dispense brand-name

Our Verdict

TMates edges out FeelGood with a score of 7.8/10 vs 7/10. If budget is your priority, FeelGood starts at $149/mo compared to TMates's $158/mo. TMates accepts insurance, which can significantly reduce your out-of-pocket costs. Choose FeelGood if you want: budget-conscious cash-pay patients who want low-cost compounded semaglutide — injection or oral tablet — with free shipping, no membership fees, and a money-back weight-loss guarantee. Choose TMates if you want: users who want flexible pricing across compounded glp-1s (medication included, $158-$249/mo with commitment discounts) and a cheap clinical-service-only path to brand wegovy or zepbound ($99/mo, patient fills at own pharmacy).

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither FeelGood nor TMates feels like the right fit, our overall #1 pick across all 49 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Try FeelGood

Starting at $149/mo

Visit FeelGood

Try TMates

Starting at $158/mo

Visit TMates

Related comparisons

Other matchups readers comparing FeelGood or TMates tend to look at next.

Top Picks

Four programs our readers click through most.

Embody

7.3/10
$299/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

Sesame Care

7.9/10
$99/mo·Brand & Compounded

Affiliate links — we earn a commission at no extra cost to you. Selection reflects what readers convert through, not editorial endorsement. Full ranking + methodology at glp1picks.com.